FogPharma Raises $178M in Series D Financing
Summary
The company intends to use the funds to advance and accelerate its pipeline of hyperstabilized α-helical polypeptide therapeutics. Led by CEO Gregory Verdine, FogPharma is a biopharmaceutical company developing Helicon polypeptides. Through this novel therapeutic modality, the company aims to address the limitations of existing drug classes and achieve universal druggability, a world where no targets are off-limits to new medicines. In addition, FogPharma is advancing other programs against important, biologically validated cancer targets including TEAD, NRAS, Pan-KRAS, ERG and Cyclin E1. Dr. Klausner served as chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health and Human Development as well as a past president of the American Society of Clinical Investigation.